INT173163

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.16
First Reported 2003
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 18
Total Number 19
Disease Relevance 2.86
Pain Relevance 0.91

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (DR1) intracellular (DR1) DNA binding (DR1)
transcription factor binding (DR1)
Anatomy Link Frequency
hepatocyte 1
proximal 1
DR1 (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 88 96.12 Very High Very High Very High
Arthritis 38 87.20 High High
Inflammation 122 86.36 High High
metalloproteinase 168 78.40 Quite High
Tendonitis 12 58.48 Quite High
Pain 14 57.36 Quite High
agonist 36 50.00 Quite Low
drug abuse 1 49.04 Quite Low
rheumatoid arthritis 64 34.72 Quite Low
Osteoarthritis 60 34.44 Quite Low
Disease Link Frequency Relevance Heat
Adrenal Cancer 135 99.38 Very High Very High Very High
Disorder Of Lipid Metabolism 8 97.84 Very High Very High Very High
Stress 14 93.04 High High
Chondrosarcoma 72 90.28 High High
Arthritis 60 87.20 High High
INFLAMMATION 141 86.36 High High
Arthropathy 24 86.00 High High
Disease 32 79.68 Quite High
Syndrome 72 66.20 Quite High
Tendinopathy 12 58.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
PPAR-RXR heterodimers were shown to compete with hepatocyte nuclear factor-4 (HNF-4) homodimers for binding to DR1 elements, resulting in decreases in transcription of apolipoprotein C-III and transferrin genes [30,31].
DR1 Binding (binding) of in hepatocyte associated with disorder of lipid metabolism
1) Confidence 0.16 Published 2003 Journal Comp Hepatol Section Body Doc Link PMC151270 Disease Relevance 0.10 Pain Relevance 0
These flanking sequences may provide an extra level of specificity to different nuclear receptors that recognize the DR1 element [36].
DR1 Binding (recognize) of
2) Confidence 0.15 Published 2003 Journal Comp Hepatol Section Body Doc Link PMC151270 Disease Relevance 0.21 Pain Relevance 0.04
heterodimer preferentially binds to the DR1 PPAR response element (PPRE) [24], and the crystal structure of this heterodimer/DNA complex is recently reported (Figure 1) [25].
DR1 Binding (binds) of
3) Confidence 0.13 Published 2009 Journal PPAR Research Section Body Doc Link PMC2801013 Disease Relevance 0 Pain Relevance 0
This situation is similar to that found with the RXR/RAR heterodimer bound to a DR1 (43), or the RXR/VDR heterodimer bound to a DR5 (44), which cannot trigger transcriptional activation through these elements.
DR1 Binding (bound) of
4) Confidence 0.13 Published 2005 Journal Nucleic Acids Research Section Body Doc Link PMC1084319 Disease Relevance 0 Pain Relevance 0
A well-known example is that the RXR homodimer and several other RXR heterodimers can recognize and bind to the DR1 element [29].
DR1 Binding (bind) of
5) Confidence 0.11 Published 2009 Journal PPAR Research Section Body Doc Link PMC2801013 Disease Relevance 0 Pain Relevance 0
At the level of DNA binding, most RXR heterodimers bind selectively to the well-known “DR1 to 5” DNA response elements.
DR1 Binding (binding) of
6) Confidence 0.11 Published 2009 Journal PPAR Research Section Abstract Doc Link PMC2801013 Disease Relevance 0 Pain Relevance 0
In addition, we hypothesized that LG268, as a ligand for RXR, may also induce increased binding of the heterodimer to the DR-1 site and that combination treatment with both ligands would further increase binding to the DR-1 site since both NHRs would be liganded.
DR-1 site Binding (binding) of
7) Confidence 0.10 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656243 Disease Relevance 0.08 Pain Relevance 0.04
In addition, we hypothesized that LG268, as a ligand for RXR, may also induce increased binding of the heterodimer to the DR-1 site and that combination treatment with both ligands would further increase binding to the DR-1 site since both NHRs would be liganded.
DR-1 site Binding (binding) of
8) Confidence 0.10 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656243 Disease Relevance 0.07 Pain Relevance 0.04
The competitive binding model implicates competition for binding to the degenerate DR-1 site between RXR:PPAR?
DR-1 site Binding (binding) of
9) Confidence 0.10 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656243 Disease Relevance 0.09 Pain Relevance 0.04
that binds to direct repeat-1 (DR-1) motifs, known as PPAR?
DR-1 Binding (binds) of
10) Confidence 0.08 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656243 Disease Relevance 0.55 Pain Relevance 0.22
In keeping with this model, we show that, in SW-1353 cells, rosiglitazone and LG268 result in similar levels of consensus DR-1-driven reporter activation, suggesting that treatment with each compound may increase binding to the DR-1 element.
DR-1 element Binding (binding) of
11) Confidence 0.08 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656243 Disease Relevance 0.06 Pain Relevance 0
heterodimer to the DR-1 element precludes binding of AP-1 proteins to its site and thereby antagonizes the expression of MMP-1.
DR-1 element Binding (heterodimer) of
12) Confidence 0.07 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656243 Disease Relevance 0.34 Pain Relevance 0.15
heterodimer to the DR-1 element precludes binding of AP-1 proteins to its site and thereby antagonizes the expression of MMP-1.
DR-1 element Binding (binding) of
13) Confidence 0.07 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656243 Disease Relevance 0.34 Pain Relevance 0.15
binding at the DR-1/AP-1 site of the endogenous MMP-1 and MMP-13 promoters in genomic DNA.
DR-1/AP-1 Binding (binding) of
14) Confidence 0.07 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656243 Disease Relevance 0 Pain Relevance 0
binding to the DR-1/AP-1 site in suppressing MMP-1 and MMP-13 production and addressed possible mechanisms of inhibition, including competitive binding between RXR:PPAR?
DR-1/AP-1 Spec (possible) Binding (binding) of
15) Confidence 0.07 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656243 Disease Relevance 0.09 Pain Relevance 0.03
were binding to the DR-1/AP-1 site in the MMP-1 and MMP-13 proximal promoters, this DNA element may also be responsive to treatment with combinations of LG268 and rosiglitazone.
DR-1/AP-1 Binding (binding) of in proximal
16) Confidence 0.07 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656243 Disease Relevance 0 Pain Relevance 0
heterodimers can regulate gene expression through binding to PPRE/DR-1 sites in the promoters of target genes [37].
DR-1 Binding (binding) of
17) Confidence 0.07 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656243 Disease Relevance 0.08 Pain Relevance 0.04
This DR-1 site overlaps a binding site for the transcription factor activator protein-1 (AP-1), which is largely responsible for the proinflammatory cytokine-induced upregulation of MMP-1 [20].
DR-1 site Binding (binding) of associated with cytokine
18) Confidence 0.06 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656243 Disease Relevance 0.32 Pain Relevance 0.16
Another general category was emotions and cognitions related to CAH, including two subcategories, negative, which was general, and positive, which was variant.
negative Binding (general) of associated with adrenal cancer
19) Confidence 0.03 Published 2010 Journal International Journal of Pediatric Endocrinology Section Body Doc Link PMC2896835 Disease Relevance 0.54 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox